| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 57 | 2022 | 4946 | 2.250 |
Why?
|
| Uganda | 60 | 2021 | 194 | 2.180 |
Why?
|
| Male | 81 | 2022 | 6489 | 1.470 |
Why?
|
| Female | 89 | 2022 | 8751 | 1.390 |
Why?
|
| Adult | 74 | 2021 | 5664 | 1.360 |
Why?
|
| Adolescent | 51 | 2021 | 2858 | 1.280 |
Why?
|
| Humans | 102 | 2022 | 14077 | 1.220 |
Why?
|
| Young Adult | 40 | 2021 | 2357 | 1.000 |
Why?
|
| Middle Aged | 40 | 2021 | 3425 | 0.890 |
Why?
|
| Latent Tuberculosis | 7 | 2021 | 45 | 0.880 |
Why?
|
| Anti-HIV Agents | 19 | 2021 | 1275 | 0.860 |
Why?
|
| Poverty Areas | 4 | 2021 | 20 | 0.860 |
Why?
|
| Prevalence | 23 | 2021 | 1149 | 0.860 |
Why?
|
| AIDS Serodiagnosis | 2 | 2020 | 44 | 0.770 |
Why?
|
| Depressive Disorder, Major | 5 | 2020 | 20 | 0.770 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 6 | 2020 | 19 | 0.760 |
Why?
|
| Child Development | 2 | 2019 | 89 | 0.760 |
Why?
|
| Health Services | 2 | 2020 | 44 | 0.700 |
Why?
|
| Data Collection | 2 | 2020 | 86 | 0.690 |
Why?
|
| Sexual Behavior | 9 | 2022 | 313 | 0.680 |
Why?
|
| Growth Disorders | 2 | 2019 | 56 | 0.670 |
Why?
|
| Anti-Retroviral Agents | 8 | 2017 | 542 | 0.660 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2021 | 326 | 0.640 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2019 | 467 | 0.610 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2018 | 235 | 0.600 |
Why?
|
| Socioeconomic Factors | 10 | 2021 | 405 | 0.600 |
Why?
|
| Cross-Sectional Studies | 21 | 2022 | 1377 | 0.600 |
Why?
|
| Sexual Partners | 9 | 2020 | 211 | 0.600 |
Why?
|
| Antiretroviral Therapy, Highly Active | 9 | 2017 | 468 | 0.590 |
Why?
|
| Logistic Models | 13 | 2021 | 252 | 0.590 |
Why?
|
| Risk Factors | 20 | 2021 | 1431 | 0.580 |
Why?
|
| Child | 24 | 2022 | 2180 | 0.570 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 265 | 0.570 |
Why?
|
| CD4 Lymphocyte Count | 17 | 2021 | 654 | 0.550 |
Why?
|
| Cohort Studies | 18 | 2020 | 939 | 0.550 |
Why?
|
| HIV-1 | 8 | 2018 | 1239 | 0.540 |
Why?
|
| Rural Population | 14 | 2018 | 624 | 0.530 |
Why?
|
| BCG Vaccine | 4 | 2020 | 20 | 0.520 |
Why?
|
| Surveys and Questionnaires | 11 | 2021 | 532 | 0.520 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 367 | 0.480 |
Why?
|
| Antigens, Bacterial | 4 | 2020 | 32 | 0.480 |
Why?
|
| Incidence | 13 | 2020 | 655 | 0.480 |
Why?
|
| Child, Preschool | 14 | 2021 | 1675 | 0.440 |
Why?
|
| Mental Disorders | 2 | 2013 | 40 | 0.440 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 507 | 0.430 |
Why?
|
| Depression | 1 | 2013 | 117 | 0.390 |
Why?
|
| Tuberculosis | 4 | 2022 | 530 | 0.390 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2020 | 320 | 0.380 |
Why?
|
| Infant | 12 | 2021 | 2145 | 0.370 |
Why?
|
| Malaria | 4 | 2017 | 207 | 0.370 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2020 | 4 | 0.370 |
Why?
|
| Community Health Workers | 2 | 2022 | 62 | 0.360 |
Why?
|
| Prospective Studies | 13 | 2020 | 1131 | 0.360 |
Why?
|
| Urban Population | 4 | 2020 | 246 | 0.360 |
Why?
|
| Communicable Diseases | 3 | 2021 | 61 | 0.360 |
Why?
|
| Abortion, Legal | 3 | 2005 | 7 | 0.360 |
Why?
|
| South Africa | 26 | 2022 | 7312 | 0.350 |
Why?
|
| Infant, Newborn | 11 | 2021 | 1410 | 0.350 |
Why?
|
| Medication Adherence | 4 | 2018 | 137 | 0.350 |
Why?
|
| Bacterial Proteins | 4 | 2020 | 117 | 0.340 |
Why?
|
| Withholding Treatment | 2 | 2020 | 26 | 0.340 |
Why?
|
| HIV | 5 | 2019 | 380 | 0.320 |
Why?
|
| HIV Seropositivity | 5 | 2015 | 263 | 0.320 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 409 | 0.320 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2020 | 91 | 0.310 |
Why?
|
| Aged | 10 | 2020 | 1650 | 0.310 |
Why?
|
| Abortion, Incomplete | 2 | 2005 | 5 | 0.300 |
Why?
|
| Pregnancy | 10 | 2021 | 1815 | 0.300 |
Why?
|
| Patient Compliance | 4 | 2018 | 120 | 0.290 |
Why?
|
| Risk-Taking | 5 | 2018 | 119 | 0.290 |
Why?
|
| Treatment Outcome | 10 | 2020 | 867 | 0.280 |
Why?
|
| Antimalarials | 2 | 2016 | 32 | 0.270 |
Why?
|
| Motivation | 2 | 2020 | 56 | 0.260 |
Why?
|
| Residence Characteristics | 2 | 2017 | 56 | 0.250 |
Why?
|
| Biomarkers | 3 | 2020 | 322 | 0.250 |
Why?
|
| Glucosylceramidase | 1 | 2004 | 3 | 0.240 |
Why?
|
| Gaucher Disease | 1 | 2004 | 4 | 0.240 |
Why?
|
| Double-Blind Method | 8 | 2020 | 263 | 0.240 |
Why?
|
| Suicide | 2 | 2017 | 7 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 247 | 0.230 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2015 | 194 | 0.230 |
Why?
|
| Vaccination | 3 | 2021 | 347 | 0.220 |
Why?
|
| Family Characteristics | 5 | 2021 | 133 | 0.220 |
Why?
|
| Dinoprostone | 1 | 2003 | 6 | 0.220 |
Why?
|
| Catheterization | 1 | 2003 | 6 | 0.220 |
Why?
|
| Labor, Induced | 1 | 2003 | 24 | 0.220 |
Why?
|
| Misoprostol | 1 | 2003 | 45 | 0.210 |
Why?
|
| Oxytocics | 1 | 2003 | 52 | 0.210 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2017 | 186 | 0.200 |
Why?
|
| Interferon-gamma | 3 | 2017 | 39 | 0.200 |
Why?
|
| Child Mortality | 2 | 2013 | 93 | 0.200 |
Why?
|
| Kenya | 2 | 2019 | 173 | 0.200 |
Why?
|
| Text Messaging | 1 | 2022 | 25 | 0.200 |
Why?
|
| Communication | 1 | 2022 | 56 | 0.200 |
Why?
|
| Hypersensitivity | 1 | 2021 | 7 | 0.200 |
Why?
|
| Behavior | 1 | 2021 | 5 | 0.200 |
Why?
|
| Hepatitis B Vaccines | 1 | 2002 | 38 | 0.200 |
Why?
|
| Lead | 3 | 2006 | 33 | 0.190 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 8 | 0.190 |
Why?
|
| Emergency Treatment | 1 | 2021 | 13 | 0.190 |
Why?
|
| Suicidal Ideation | 1 | 2021 | 7 | 0.190 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 19 | 0.190 |
Why?
|
| Interleukin-6 | 2 | 2020 | 50 | 0.190 |
Why?
|
| Community Participation | 2 | 2020 | 42 | 0.190 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 449 | 0.190 |
Why?
|
| C-Reactive Protein | 2 | 2020 | 96 | 0.190 |
Why?
|
| Reproductive Health Services | 1 | 2022 | 66 | 0.190 |
Why?
|
| Immunization Programs | 1 | 2002 | 78 | 0.190 |
Why?
|
| Population Surveillance | 3 | 2020 | 325 | 0.190 |
Why?
|
| Health Expenditures | 1 | 2021 | 34 | 0.190 |
Why?
|
| Rural Health | 5 | 2015 | 118 | 0.180 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 21 | 0.180 |
Why?
|
| Antigens, Heterophile | 1 | 2020 | 2 | 0.180 |
Why?
|
| Antitubercular Agents | 2 | 2015 | 299 | 0.180 |
Why?
|
| Transients and Migrants | 1 | 2020 | 39 | 0.180 |
Why?
|
| Selection Bias | 1 | 2020 | 4 | 0.180 |
Why?
|
| Conduct Disorder | 1 | 2020 | 1 | 0.180 |
Why?
|
| Decision Making, Organizational | 1 | 2020 | 2 | 0.180 |
Why?
|
| Health Information Systems | 1 | 2020 | 2 | 0.180 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 243 | 0.180 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 59 | 0.180 |
Why?
|
| Databases, Factual | 1 | 2020 | 64 | 0.170 |
Why?
|
| Serologic Tests | 1 | 2020 | 26 | 0.170 |
Why?
|
| Nevirapine | 3 | 2010 | 146 | 0.170 |
Why?
|
| Health Facilities | 1 | 2020 | 39 | 0.170 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 163 | 0.170 |
Why?
|
| Intimate Partner Violence | 1 | 2020 | 52 | 0.170 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2017 | 25 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 125 | 0.170 |
Why?
|
| Mood Disorders | 1 | 2019 | 3 | 0.170 |
Why?
|
| Cleft Lip | 1 | 2019 | 6 | 0.160 |
Why?
|
| Cleft Palate | 1 | 2019 | 6 | 0.160 |
Why?
|
| Chemoprevention | 2 | 2016 | 33 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 113 | 0.160 |
Why?
|
| Environmental Monitoring | 4 | 2006 | 20 | 0.160 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2019 | 7 | 0.160 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 10 | 0.160 |
Why?
|
| Domestic Violence | 2 | 2013 | 8 | 0.160 |
Why?
|
| Universities | 1 | 2019 | 34 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2017 | 145 | 0.160 |
Why?
|
| Empathy | 1 | 2018 | 2 | 0.160 |
Why?
|
| Stress Disorders, Traumatic | 1 | 2018 | 3 | 0.160 |
Why?
|
| Burnout, Professional | 1 | 2018 | 7 | 0.160 |
Why?
|
| Job Satisfaction | 1 | 2018 | 8 | 0.160 |
Why?
|
| Nursing Staff, Hospital | 1 | 2018 | 8 | 0.150 |
Why?
|
| Abortion, Induced | 1 | 2018 | 16 | 0.150 |
Why?
|
| Disease Notification | 1 | 2018 | 12 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2020 | 228 | 0.150 |
Why?
|
| Mass Screening | 1 | 2020 | 242 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 22 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 44 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2018 | 42 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 42 | 0.150 |
Why?
|
| Coitus | 1 | 2017 | 15 | 0.150 |
Why?
|
| Drug Administration Schedule | 5 | 2015 | 153 | 0.150 |
Why?
|
| Child, Orphaned | 1 | 2017 | 16 | 0.150 |
Why?
|
| Cytokines | 4 | 2021 | 107 | 0.150 |
Why?
|
| Age Factors | 4 | 2021 | 364 | 0.150 |
Why?
|
| Schistosomiasis mansoni | 1 | 2017 | 1 | 0.150 |
Why?
|
| Acyltransferases | 1 | 2017 | 4 | 0.150 |
Why?
|
| Tuberculosis Vaccines | 1 | 2017 | 8 | 0.150 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2017 | 8 | 0.150 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2017 | 6 | 0.140 |
Why?
|
| Placebos | 4 | 2018 | 44 | 0.140 |
Why?
|
| Regulon | 1 | 2017 | 1 | 0.140 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2011 | 210 | 0.140 |
Why?
|
| Protein Kinases | 1 | 2017 | 4 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 102 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 2017 | 38 | 0.140 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 42 | 0.140 |
Why?
|
| Anemia | 2 | 2014 | 41 | 0.140 |
Why?
|
| Linear Models | 3 | 2020 | 82 | 0.140 |
Why?
|
| Environmental Pollutants | 2 | 2006 | 16 | 0.140 |
Why?
|
| Zimbabwe | 3 | 2013 | 115 | 0.140 |
Why?
|
| Contraception Behavior | 1 | 2017 | 54 | 0.140 |
Why?
|
| Culture | 1 | 2016 | 21 | 0.140 |
Why?
|
| Home Care Services | 3 | 2014 | 15 | 0.140 |
Why?
|
| Time Factors | 4 | 2020 | 503 | 0.140 |
Why?
|
| Multivariate Analysis | 4 | 2021 | 171 | 0.130 |
Why?
|
| Contraception | 1 | 2017 | 90 | 0.130 |
Why?
|
| Social Class | 2 | 2015 | 72 | 0.130 |
Why?
|
| Chemokine CCL4 | 1 | 2015 | 14 | 0.130 |
Why?
|
| Health Personnel | 1 | 2018 | 229 | 0.130 |
Why?
|
| Manganese | 2 | 2006 | 11 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 60 | 0.130 |
Why?
|
| Circumcision, Male | 1 | 2016 | 97 | 0.120 |
Why?
|
| Hope | 1 | 2015 | 3 | 0.120 |
Why?
|
| Isoniazid | 1 | 2015 | 110 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2011 | 21 | 0.120 |
Why?
|
| Hemoglobins | 1 | 2014 | 40 | 0.120 |
Why?
|
| Immunization | 1 | 2014 | 63 | 0.120 |
Why?
|
| Research Design | 1 | 2015 | 123 | 0.120 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2014 | 113 | 0.120 |
Why?
|
| Antibody Formation | 3 | 2020 | 61 | 0.110 |
Why?
|
| Appointments and Schedules | 1 | 2013 | 5 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 235 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2014 | 54 | 0.110 |
Why?
|
| Condoms | 2 | 2011 | 86 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 137 | 0.110 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 13 | 0.110 |
Why?
|
| Naphthalenesulfonates | 1 | 2013 | 2 | 0.110 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2013 | 16 | 0.110 |
Why?
|
| Antibodies, Bacterial | 3 | 2020 | 149 | 0.110 |
Why?
|
| HIV Seronegativity | 1 | 2013 | 52 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2022 | 767 | 0.110 |
Why?
|
| Infant Mortality | 1 | 2013 | 92 | 0.100 |
Why?
|
| Polymers | 1 | 2013 | 133 | 0.100 |
Why?
|
| Coinfection | 1 | 2014 | 268 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2021 | 217 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 103 | 0.100 |
Why?
|
| Developing Countries | 3 | 2010 | 385 | 0.100 |
Why?
|
| Fluconazole | 1 | 2011 | 17 | 0.100 |
Why?
|
| Cryptococcosis | 1 | 2011 | 17 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 112 | 0.100 |
Why?
|
| Population Dynamics | 1 | 2011 | 27 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2012 | 169 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2011 | 40 | 0.100 |
Why?
|
| Vitamin A | 1 | 2011 | 10 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2021 | 149 | 0.100 |
Why?
|
| Viral Vaccines | 1 | 2011 | 21 | 0.090 |
Why?
|
| Hypertension | 1 | 2015 | 397 | 0.090 |
Why?
|
| Educational Status | 3 | 2019 | 68 | 0.090 |
Why?
|
| Bacteremia | 1 | 2011 | 79 | 0.090 |
Why?
|
| Safe Sex | 1 | 2010 | 67 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 18 | 0.090 |
Why?
|
| Maternal Health Services | 1 | 2010 | 51 | 0.090 |
Why?
|
| Splenomegaly | 1 | 2009 | 1 | 0.090 |
Why?
|
| Community Health Services | 1 | 2009 | 58 | 0.080 |
Why?
|
| Perception | 2 | 2020 | 42 | 0.080 |
Why?
|
| Immunoglobulin G | 3 | 2017 | 220 | 0.080 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2020 | 5 | 0.080 |
Why?
|
| Administration, Intravaginal | 2 | 2013 | 50 | 0.080 |
Why?
|
| Acidosis, Lactic | 1 | 2008 | 5 | 0.080 |
Why?
|
| Comorbidity | 2 | 2020 | 184 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2008 | 33 | 0.080 |
Why?
|
| HIV Antibodies | 1 | 2010 | 243 | 0.070 |
Why?
|
| Paint | 1 | 2006 | 3 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2020 | 64 | 0.070 |
Why?
|
| AIDS Vaccines | 1 | 2009 | 150 | 0.070 |
Why?
|
| Spouse Abuse | 1 | 2006 | 12 | 0.070 |
Why?
|
| Epidemiologic Methods | 3 | 2011 | 25 | 0.070 |
Why?
|
| Honey | 1 | 2006 | 1 | 0.070 |
Why?
|
| Propylene Glycol | 1 | 2006 | 1 | 0.070 |
Why?
|
| Violence | 1 | 2007 | 68 | 0.070 |
Why?
|
| Wound Healing | 1 | 2006 | 24 | 0.070 |
Why?
|
| Hydrogels | 1 | 2006 | 42 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2006 | 26 | 0.070 |
Why?
|
| Rape | 2 | 2006 | 10 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2018 | 53 | 0.070 |
Why?
|
| Vehicle Emissions | 1 | 2005 | 1 | 0.070 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2005 | 4 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2021 | 131 | 0.060 |
Why?
|
| Parity | 1 | 2005 | 19 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 16 | 0.060 |
Why?
|
| Long-Term Care | 1 | 2004 | 13 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2018 | 175 | 0.060 |
Why?
|
| Prenatal Care | 2 | 2021 | 141 | 0.060 |
Why?
|
| Maternal Mortality | 1 | 2005 | 54 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 124 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2005 | 45 | 0.060 |
Why?
|
| Attitude | 2 | 2020 | 12 | 0.060 |
Why?
|
| Health Care Reform | 1 | 2003 | 20 | 0.060 |
Why?
|
| Counseling | 2 | 2018 | 136 | 0.060 |
Why?
|
| Titrimetry | 1 | 2003 | 2 | 0.060 |
Why?
|
| Analgesia, Obstetrical | 1 | 2003 | 7 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 25 | 0.060 |
Why?
|
| Animals | 2 | 2017 | 1063 | 0.050 |
Why?
|
| Obstetric Labor Complications | 1 | 2003 | 25 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2003 | 113 | 0.050 |
Why?
|
| Battered Women | 1 | 2002 | 1 | 0.050 |
Why?
|
| Sex Offenses | 1 | 2002 | 29 | 0.050 |
Why?
|
| Delivery, Obstetric | 1 | 2003 | 78 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2003 | 112 | 0.050 |
Why?
|
| Diarrhea | 1 | 2003 | 76 | 0.050 |
Why?
|
| Reference Values | 2 | 2014 | 64 | 0.050 |
Why?
|
| Zidovudine | 2 | 2014 | 59 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2013 | 26 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 4 | 0.050 |
Why?
|
| Child Abuse, Sexual | 1 | 2002 | 4 | 0.050 |
Why?
|
| Hepatitis B Antibodies | 1 | 2002 | 10 | 0.050 |
Why?
|
| Stavudine | 2 | 2014 | 78 | 0.050 |
Why?
|
| Mycobacterium bovis | 1 | 2021 | 4 | 0.050 |
Why?
|
| Protective Factors | 1 | 2021 | 7 | 0.050 |
Why?
|
| Reproductive Health | 1 | 2022 | 51 | 0.050 |
Why?
|
| Lot Quality Assurance Sampling | 1 | 2021 | 1 | 0.050 |
Why?
|
| Nigeria | 1 | 2021 | 40 | 0.050 |
Why?
|
| Maternal Exposure | 1 | 2021 | 14 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2021 | 53 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2002 | 89 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 210 | 0.050 |
Why?
|
| Tenofovir | 2 | 2014 | 158 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2021 | 16 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2021 | 78 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2020 | 16 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2015 | 190 | 0.050 |
Why?
|
| Algorithms | 1 | 2021 | 105 | 0.050 |
Why?
|
| Vaginal Smears | 1 | 2021 | 34 | 0.050 |
Why?
|
| Antibody Affinity | 1 | 2020 | 11 | 0.050 |
Why?
|
| Tetanus Toxoid | 1 | 2020 | 10 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 237 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 33 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 24 | 0.050 |
Why?
|
| Viral Load | 3 | 2010 | 808 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 21 | 0.040 |
Why?
|
| Social Norms | 1 | 2020 | 8 | 0.040 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2020 | 1 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 24 | 0.040 |
Why?
|
| Drugs, Essential | 1 | 2020 | 4 | 0.040 |
Why?
|
| Resuscitation | 1 | 2020 | 18 | 0.040 |
Why?
|
| Policy | 1 | 2020 | 42 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 180 | 0.040 |
Why?
|
| Inflammation | 1 | 2020 | 103 | 0.040 |
Why?
|
| National Health Programs | 1 | 2020 | 78 | 0.040 |
Why?
|
| Body Height | 1 | 2019 | 51 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 464 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 34 | 0.040 |
Why?
|
| Health Status | 1 | 2019 | 111 | 0.040 |
Why?
|
| Poverty | 1 | 2019 | 149 | 0.040 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 5 | 0.040 |
Why?
|
| Paternal Deprivation | 1 | 2017 | 1 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 154 | 0.040 |
Why?
|
| Child Behavior Disorders | 1 | 2017 | 7 | 0.040 |
Why?
|
| Africa, Southern | 1 | 2017 | 89 | 0.040 |
Why?
|
| Suburban Population | 1 | 2017 | 9 | 0.040 |
Why?
|
| Schistosoma mansoni | 1 | 2017 | 1 | 0.040 |
Why?
|
| Parents | 1 | 2017 | 29 | 0.040 |
Why?
|
| Vaccines, DNA | 1 | 2017 | 10 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 25 | 0.040 |
Why?
|
| Mothers | 1 | 2019 | 190 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 20 | 0.040 |
Why?
|
| Self Report | 1 | 2017 | 111 | 0.040 |
Why?
|
| Caregivers | 1 | 2017 | 66 | 0.040 |
Why?
|
| Sputum | 1 | 2017 | 135 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 183 | 0.030 |
Why?
|
| Unsafe Sex | 1 | 2017 | 45 | 0.030 |
Why?
|
| Occupations | 1 | 2016 | 13 | 0.030 |
Why?
|
| Fishes | 1 | 2015 | 3 | 0.030 |
Why?
|
| Lakes | 1 | 2015 | 3 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2015 | 10 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 155 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2015 | 18 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2015 | 79 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2015 | 29 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 150 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 17 | 0.030 |
Why?
|
| Marital Status | 1 | 2015 | 11 | 0.030 |
Why?
|
| Tanzania | 1 | 2015 | 84 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 57 | 0.030 |
Why?
|
| Epidemiologic Factors | 1 | 2014 | 2 | 0.030 |
Why?
|
| Helminthiasis | 1 | 2014 | 7 | 0.030 |
Why?
|
| Hematologic Tests | 1 | 2014 | 11 | 0.030 |
Why?
|
| Climate | 1 | 2014 | 5 | 0.030 |
Why?
|
| Rwanda | 1 | 2014 | 30 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2015 | 100 | 0.030 |
Why?
|
| Smoking | 1 | 2015 | 99 | 0.030 |
Why?
|
| Overweight | 1 | 2015 | 84 | 0.030 |
Why?
|
| Zambia | 1 | 2014 | 112 | 0.030 |
Why?
|
| Seasons | 1 | 2014 | 149 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 25 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 62 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2013 | 3 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2015 | 294 | 0.030 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2013 | 24 | 0.030 |
Why?
|
| Housing | 1 | 2013 | 24 | 0.030 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 20 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2012 | 44 | 0.030 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 29 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 132 | 0.030 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 49 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 263 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 180 | 0.030 |
Why?
|
| Phylogeny | 1 | 2012 | 231 | 0.030 |
Why?
|
| Emigration and Immigration | 1 | 2011 | 13 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2012 | 303 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 6 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 430 | 0.020 |
Why?
|
| Suicide, Attempted | 1 | 2011 | 3 | 0.020 |
Why?
|
| Psychology | 1 | 2011 | 4 | 0.020 |
Why?
|
| Epidemics | 1 | 2011 | 64 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 45 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2010 | 56 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2010 | 43 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2011 | 101 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 123 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 124 | 0.020 |
Why?
|
| Decision Making | 1 | 2010 | 52 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 17 | 0.020 |
Why?
|
| Palliative Care | 1 | 2010 | 50 | 0.020 |
Why?
|
| Registries | 1 | 2010 | 89 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 11 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 40 | 0.020 |
Why?
|
| Organophosphonates | 1 | 2009 | 45 | 0.020 |
Why?
|
| Lamivudine | 1 | 2009 | 86 | 0.020 |
Why?
|
| Adenine | 1 | 2009 | 88 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 380 | 0.020 |
Why?
|
| Population Groups | 1 | 2008 | 9 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2008 | 37 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2008 | 184 | 0.020 |
Why?
|
| Play and Playthings | 1 | 2006 | 3 | 0.020 |
Why?
|
| Occlusive Dressings | 1 | 2006 | 1 | 0.020 |
Why?
|
| Polyurethanes | 1 | 2006 | 3 | 0.020 |
Why?
|
| Sex Factors | 1 | 2007 | 224 | 0.020 |
Why?
|
| Gold | 1 | 2006 | 37 | 0.020 |
Why?
|
| Mining | 1 | 2006 | 41 | 0.020 |
Why?
|
| Petroleum | 1 | 2005 | 1 | 0.020 |
Why?
|
| Chlamydia trachomatis | 1 | 2005 | 13 | 0.020 |
Why?
|
| Chlamydia Infections | 1 | 2005 | 17 | 0.020 |
Why?
|
| Public Policy | 1 | 2005 | 24 | 0.020 |
Why?
|
| Gonorrhea | 1 | 2005 | 20 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 89 | 0.020 |
Why?
|
| Health Education | 1 | 2005 | 35 | 0.020 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2005 | 1 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 2005 | 3 | 0.020 |
Why?
|
| Adolescent Behavior | 1 | 2005 | 58 | 0.020 |
Why?
|
| Water Pollutants, Chemical | 1 | 2005 | 3 | 0.020 |
Why?
|
| Soil Pollutants | 1 | 2005 | 6 | 0.020 |
Why?
|
| Dust | 1 | 2005 | 15 | 0.020 |
Why?
|
| Health Services Research | 1 | 2003 | 57 | 0.010 |
Why?
|
| Social Control, Informal | 1 | 2002 | 5 | 0.010 |
Why?
|
| Causality | 1 | 2002 | 7 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2002 | 13 | 0.010 |
Why?
|
| Morbidity | 1 | 2002 | 37 | 0.010 |
Why?
|
| Sexual Harassment | 1 | 2002 | 1 | 0.010 |
Why?
|
| Health Surveys | 1 | 2002 | 59 | 0.010 |
Why?
|